作者的详细信息

Moiseenko, Fedor V.

期 栏目 标题 文件
卷 23, 编号 1 (2021) CLINICAL ONCOLOGY Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data PDF
(Rus)
卷 23, 编号 2 (2021) CLINICAL ONCOLOGY Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report PDF
(Rus)
卷 23, 编号 3 (2021) CLINICAL ONCOLOGY Malignant neoplasm of the bronchi and lung: Russian clinical guidelines PDF
(Rus)
卷 23, 编号 4 (2021) CLINICAL ONCOLOGY Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON PDF
(Rus)
卷 24, 编号 3 (2022) CLINICAL ONCOLOGY Malignant neoplasm of the bronchi and lung: Russian clinical guidelines PDF
(Rus)
卷 24, 编号 4 (2022) CLINICAL ONCOLOGY Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study PDF
(Rus)
卷 25, 编号 3 (2023) CLINICAL ONCOLOGY Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study PDF
(Rus)
卷 26, 编号 1 (2024) Articles Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia PDF
(Rus)

##common.cookie##